HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DSM expands R&D efforts

This article was originally published in The Rose Sheet

Executive Summary

DSM Nutritional Products expands its North American research and development facilities with the Nutrition Innovation Center at its Parsippany, N.J. headquarters. The supplier says Feb. 8 the new center will "bring together DSM's extensive laboratory capabilities for the thriving beverage, bakery, dairy, savory, dietary supplement and personal-care market sectors." DSM's personal-care ingredient roster includes vitamins, UV filters, emulsifiers and carotenoids. The firm expects to open the center in 2011

You may also be interested in...



DSM Sharpens Personal-Care Focus With New Products, Growth Initiatives

Recognizing the current opportunity in personal care, Royal DSM N.V. is growing that branch of its business with an updated product portfolio, a new corporate image and international expansion initiatives.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel